HNSBF
Price:
$3.7
Market Cap:
$3.43B
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therap...[Read more]
Industry
Medical - Pharmaceuticals
IPO Date
2015-03-25
Stock Exchange
OTC
Ticker
HNSBF
According to Hansa Biopharma AB’s latest financial reports and current stock price. The company's current ROE is 213.16%. This represents a change of 155.82% compared to the average of 83.32% of the last 4 quarters.
The mean historical ROE of Hansa Biopharma AB over the last ten years is 86.49%. The current 213.16% ROE has changed 146.46% with respect to the historical average. Over the past ten years (40 quarters), HNSBF's ROE was at its highest in in the September 2023 quarter at 402.94%. The ROE was at its lowest in in the June 2023 quarter at -137.87%.
Average
86.49%
Median
-31.36%
Minimum
-101.36%
Maximum
600.18%
Discovering the peaks and valleys of Hansa Biopharma AB ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 338.54%
Maximum Annual ROE = 600.18%
Minimum Annual Increase = -588.77%
Minimum Annual ROE = -101.36%
| Year | ROE | Change |
|---|---|---|
| 2025 | 600.18% | 338.54% |
| 2024 | 136.86% | -72.38% |
| 2023 | 495.44% | -588.77% |
| 2022 | -101.36% | 40.06% |
| 2021 | -72.37% | 113.61% |
| 2020 | -33.88% | -47.03% |
| 2019 | -63.97% | 121.81% |
| 2018 | -28.84% | 2.95% |
| 2017 | -28.01% | -28.49% |
| 2016 | -39.17% | 25.04% |
The current ROE of Hansa Biopharma AB (HNSBF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
410.82%
5-year avg
211.75%
10-year avg
86.49%
Hansa Biopharma AB’s ROE is greater than Silence Therapeutics plc (-121.71%), greater than Transgene S.A. (-63.53%), greater than Probi AB (publ) (1.21%), greater than Cellectis S.A. (-80.61%), less than Santhera Pharmaceuticals Holding AG (684.83%), greater than Immutep Ltd (-69.20%), greater than Genfit S.a. (-596.44%), greater than Frontage Holdings Corporation (1.98%), greater than hVIVO plc (-14.65%), greater than Mayne Pharma Group Limited (-23.02%),
| Company | ROE | Market cap |
|---|---|---|
| -121.71% | $212.56M | |
| -63.53% | $122.57M | |
| 1.21% | $286.93M | |
| -80.61% | $251.93M | |
| 684.83% | $344.83M | |
| -69.20% | $73.69M | |
| -596.44% | $799.03M | |
| 1.98% | $304.16M | |
| -14.65% | $75.45M | |
| -23.02% | $185.24M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Hansa Biopharma AB using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Hansa Biopharma AB or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Hansa Biopharma AB's ROE?
How is the ROE calculated for Hansa Biopharma AB (HNSBF)?
What is the highest ROE for Hansa Biopharma AB (HNSBF)?
What is the 3-year average ROE for Hansa Biopharma AB (HNSBF)?
What is the 5-year average ROE for Hansa Biopharma AB (HNSBF)?
How does the current ROE for Hansa Biopharma AB (HNSBF) compare to its historical average?